



OmniLenz® – A new surgery-free mode of Omnigen®-amniotic membrane application for treating corneal disorders ‘in-the-clinic’ or ‘emergency room’.

As part of our distribution agreement with NuVision, Altacor are excited to announce the launch of the latest innovation OmniLenz to the ophthalmology market. OmniLenz is a fascinating and pioneering product which we are delighted to be working with, especially in light of the multiplicity of applications and the potential for what it can treat. The complementarity and cooperation between the NuVision and Altacor teams is very strong and we believe will lead to great success.

OmniLenz now enables ophthalmologists to access Omnigen, a versatile ‘off-the-shelf’ regenerative therapy, that can be applied in theatre, in the clinic and even in emergency situations at the point-of-care, or in the field.

Patients may benefit from treatment earlier and therefore potentially more effectively, from first presentation. With the OmniLenz application of Omnigen, we aim to dramatically shorten the treatment pathway to improve patient care whilst saving NHS theatre time and therefore money.

OmniLenz is manufactured exclusively for OmniLenz in the UK by Menicon Limited, utilising the tried and tested comfort and safety of an established Menicon Soft 72 contact lens. The first version, OmniLenz C, has been specifically designed for the application of Omnigen 80 (10 mm disc) to treat central corneal defects.

Developed through Innovate UK Biomedical Catalysts funding, OmniLenz may revolutionise the treatment approach for corneal disorders in human patients. The lens is easy to apply and remove, with the concept proven during trial stages, where it was well tolerated at the ocular surface long-term.

“OmniLenz was designed to deliver Omnigen as a simple and cost effective, early intervention preventative therapy for a variety of ocular surface conditions. OmniLenz has made treating devastating ocular surface defects as easy as applying a contact lens” said Dr Andrew Hopkinson, CEO.

“The simplicity of using OmniLenz to apply Omnigen means that Omnigen can be applied directly to the surface of the eye without the need for multifaceted surgery. It allows patients to be treated quickly in the clinic in situations where surgery is not accessible or unavailable” said Dr Emily Britchford, Research and Development manager at NuVision.

We are confident that OmniLenz will be hugely beneficial in clinics ensuring Omnigen regeneration is delivered to the patient comfortably and efficiently.

<ENDS>

Notes to Editors

About NuVision

Based in MediCity, Boots Campus, Nottingham, NuVision Biotherapies is a regenerative medicine company recently spun out from Academic Ophthalmology, School of Medicine, University of Nottingham. NuVision was established in 2015, founded on investment from Mercia Fund Management, to develop and bring to market cutting edge and disruptive regenerative therapies. Initially focusing on treating front of the eye disease and trauma, NuVision intend to utilise their expertise to expand into the chronic wound arena.

www.nu-vision.co.uk

Twitter and Instagram @NuVisBio

About Omnigen

Omnigen is a ground-breaking, patented, dry preparation of human-derived amniotic membrane, made from the sac surrounding the baby during pregnancy. The Tereo® manufacturing process transforms this waste product of birth into a sterile and stable dry regenerative therapy that can be easily shipped and accessed anywhere in the world. Omnigen is applied directly to the wound dry and is rapidly and effectively rehydrated using surrounding moisture to immediately reactivate the beneficial properties to promote tissue repair and healing in a variety of ways. The product represents a unique and versatile "off-the-shelf" regenerative product that can be manufactured in a scalable manner, may be stored long term, and is administered without tissue matching or the need for immune suppression. The Tereo process improves the wound healing action and provides surgeons with an effective sight saving therapy that could provide a meaningful benefit to patients, including those suffering from serious sight destroying ocular surface diseases and conditions with unmet medical need.

About Altacor

Altacor is an ophthalmic specialty pharmaceutical company with a portfolio of marketed and development products that focus on the ocular surface disease and surgical therapy areas.

Altacor markets numerous products in the UK and Ireland (Clinitas®, Clinitas® OTC range, Clinitas® Hot Eye Compress and Biolon®) which are commercialised through its own sales and marketing organisation and network. Clinitas®, Clinitas® Multi and Clinitas GEL are prescription products, including preservative free options. Clinitas products can be used for moderate dry eye conditions and have the highest concentration of hyaluronic acid (0.4%) in the UK. Biolon® is high quality viscoelastic for use in cataract surgery with convenient 6 month room temperature storage. The company is actively pursuing European expansion.

Altacor has been the distributor of Omnigen in England, Wales and Scotland since March 2017.

www.altacor-pharma.com
t: 01223421411
e: info@altacor-pharma.com